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Industrial scale high-throughput screening delivers
multiple fast acting macroﬁlaricides
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Nematodes causing lymphatic ﬁlariasis and onchocerciasis rely on their bacterial endo-
symbiont, Wolbachia, for survival and fecundity, making Wolbachia a promising therapeutic
target. Here we perform a high-throughput screen of AstraZeneca’s 1.3 million in-house
compound library and identify 5 novel chemotypes with faster in vitro kill rates (<2 days)
than existing anti-Wolbachia drugs that cure onchocerciasis and lymphatic ﬁlariasis. This
industrial scale anthelmintic neglected tropical disease (NTD) screening campaign is the
result of a partnership between the Anti-Wolbachia consortium (A∙WOL) and AstraZeneca.
The campaign was informed throughout by rational prioritisation and triage of compounds
using cheminformatics to balance chemical diversity and drug like properties reducing the
chance of attrition from the outset. Ongoing development of these multiple chemotypes,
all with superior time-kill kinetics than registered antibiotics with anti-Wolbachia activity,
has the potential to improve upon the current therapeutic options and deliver improved, safer
and more selective macroﬁlaricidal drugs.
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Large-scale mass drug administration (MDA) programmesaimed at the control and elimination of the debilitatingneglected tropical diseases (NTDs) onchocerciasis and
lymphatic ﬁlariasis are hampered by the lack of a drug, which can
safely kill the adult stages of the nematode parasites. The ﬁlarial
nematodes which cause these diseases include Wuchereria ban-
crofti, Brugia malayi and Brugia timori for lymphatic ﬁlariasis
whilst Onchocerca volvulus causes onchocerciasis1,2. These dis-
eases afﬂict 157 million people worldwide and collectively are
responsible for the loss of 3.3 million disability adjusted life years
(DALYs) from the World’s poorest communities3,4. Triple com-
binations of existing anthelminthic MDA drugs (ivermectin,
diethylcarbamazine (DEC) and albendazole), have been shown to
be superior to existing regimens for lymphatic ﬁlariasis in a phase
II trial5, but there are serious concerns in using these combina-
tions for onchocerciasis and for lymphatic ﬁlariasis in areas of
sub-Saharan Africa co-endemic for Loa loa. Concerns are due to
severe adverse events (SAE) induced by rapid killing of O. vol-
vulus microﬁlariae (Mf) in ocular tissues and Mazzotti reactions
in the skin with DEC6 and fatal encephalopathy in Loiasis fol-
lowing ivermectin, prompting the need for pre-screening proce-
dures in at risk communities7. Fear of SAE in these communities
are thought to contribute to poor-adherence to MDA in regions
with prior experience of SAE8,9.
An alternative treatment strategy, which avoids the risk of
adverse events related to direct acting anti-ﬁlarial drugs, is to
target the Wolbachia bacterial endosymbiont of the nematodes
which cause onchocerciasis and lymphatic ﬁlariasis as it is vital
for the nematodes’ survival and fecundity1. Proof-of-concept ﬁeld
trials with the antibiotic doxycycline for 4–6 weeks, proves the
value of this endosymbiont as a therapeutic target10–16. Depletion
of this endosymbiotic bacteria was conﬁrmed in these trials and
resulted in the permanent sterilisation of the adult worms,
blocking parasite transmission, followed by a slow innocuous
death of the adult worm over 12–24 months. However, the
duration of treatment with tetracyclines and contraindications in
children and women of child-bearing age are barriers to the
widespread scale-up of this approach. The A∙WOL consortium
was established to identify novel chemical starting points with
anti-Wolbachia activity that could deliver shorter treatment
regimens for these disabling ﬁlarial diseases1,2,17.
The A∙WOL consortium have developed and successfully uti-
lised a fully validated whole cell screening assay using an insect
cell line stably infected with Wolbachia, C6/36 (wAlbB)18–20. To
facilitate the massive scale up of this screen from a capacity to
screen thousands of compounds to an industrial standard
high-throughput screen (HTS) capable of screening millions of
compounds, A∙WOL partnered with AstraZeneca’s Global High-
Throughput Screening (HTS) Centre. This collaboration estab-
lished an industrial scale anthelmintic HTS for NTDs in their
facility which had the capacity to screen the entire AstraZeneca
1.3 million compound collection.
Results
Overview of the primary HTS. This screen incorporated a three-
part assay summarised in Fig. 1. Initially C6/36 (wAlbB) cells
(insect cells stably infected with the Wolbachia target) from a
single cryopreserved batch were recovered over 7 days prior to
plating into 384-well assay ready plates (containing the test
compounds), using a semi-automated process allowing for daily
batches of ~150 plates, set up 4 days per week for 8 weeks. After a
7-day incubation period with the test compounds the plates were
moved into the second fully automated stage (using the Agilent
Technologies BioCel system) involving formaldehyde ﬁxation,
DNA staining of the insect cell nuclei (Hoechst) for toxicity
analysis and antibody staining speciﬁc to the intracellular Wol-
bachia (wBmPAL primary antibody and far-red secondary anti-
body). In the ﬁnal stage the ﬁxed and stained plates from stage 2
were processed through automated data acquisition (High Res
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Fig. 1 The high-throughput anti-Wolbachia screening ﬂow. This extensive 16-step screen per batch across all three stages was completed over 3 weeks
followed by overﬂow plate reading and data analysis in the 4th week when at full capacity of four daily batches of 150 plates per week. Manual processes
are indicated by dashed boxes and fully automated steps in solid boxes. Bold rectangular boxes indicate the use of the fully automated systems: Agilent
technologies BioCel system and HighRes Biosolutions automated system. The ﬂuorescent images are representatives of the host nuclei (Hoechst) and
Wolbachia (wBmPAL) staining taken from a whole well image (growth area of 10mm2) on the acumen® to demonstrate cells incubated with the vehicle/
DMSO and doxycycline controls
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Biosolutions system, incorporating EnVision™ and acumen® plate
readers). This industry standardised assay was then used to screen
AstraZeneca’s full library of 1.3 million compounds within
10 weeks. In total this HTS included 30 × 3 week assays covering
3835 × 384-well plates. This primary HTS generated 20,255 hits
deﬁned as >80% reduction in Wolbachia with <60% toxicity to
the host insect cell (eliminating false positives). This represents
an overall hit rate of 1.56%. These compounds are depicted in
chemical space in Fig. 2 (black points)21.
Chemoinformatic analysis of the primary hits was used to
identify the best ~6000 compounds for further evaluation in
a secondary concentration response screen using the same HTS
assay. Known antibacterials, pan assay interference compounds
(PAINS), frequent hitters, known toxic compounds, compounds
with an explosive risk, genotoxic compounds, reactive metabolites
and hits with unwanted chemical groups were ﬁltered out of
the hit set22–26. The ﬁltering rationale was based on prior
knowledge and experience from both the AstraZeneca and
A·WOL chemistry teams. The ﬁnal selection was further triaged
based on a balance of molecular weight, predicted logD,
solubility, intrinsic clearance (models for human microsomes
and rat hepatocytes) and chemotype diversity (details of
compound selection, ranking and diversity assessment of the
~6000 compounds are provided in Supplementary Tables 1 and
2). A wide range of pIC50s was obtained from these ~6000
concentration response experiments, with 990 compounds
showing a pIC50 > 6 (i.e. <1 µM IC50) against the Wolbachia
target. In parallel these ~6000 compounds were also analysed for
activity in a mammalian cell viability counter-screen to ﬂag
potential mammalian toxicity liabilities.
HTS hit triaging: secondary and tertiary screening. The ~6000
compounds tested in the secondary concentration response
screen were clustered based on their chemical structures repre-
sented by ECFP6 ﬁngerprints27, with clusters of less than three
compounds removed. The remaining clusters were prioritised
based on manual assessment of anti-Wolbachia activity, mam-
malian toxicity, cluster size and chemical structure, as well as
the measured compound purity. This process delivered 57
prioritised clusters containing 3–19 representatives and covering
a total of 360 compounds. Figure 2 represents the chemical space
covered by these compounds (orange spheres). The tertiary
prioritisation was carried out in a B. malayi Mf in vitro assay
in order to assess the activity against the Wolbachia within a
human ﬁlarial nematode, thus reducing attrition from issues,
such as speciﬁcity to insect Wolbachia, indirect insect cell activity
or barriers to drug penetration into nematodes. The two
most potent representatives were selected from each of the
57 clusters for analysis. From the 113 available representative
compounds tested at 5 µM, 85 showed less than 50% Wolbachia
reduction (normalised to the doxycycline control). 11 compounds
had between 50% and 80% Wolbachia reduction, while 17
compounds had >80% Wolbachia reduction. It is noteworthy
that the conﬁrmed hits spanned a large proportion of the che-
mical space covered by the original ~6000 compounds (Fig. 2).
This diversity reduces the risk of attrition by aiming for differ-
ential targets.
Discovery of ﬁve fast-acting chemical starting points. Based on
the anti-Wolbachia potency (cell and Mf) and in silico predictions
of drug metabolism and pharmacokinetic (DMPK) properties,
18 compounds from 9 distinct clusters (two compounds in
each cluster) were selected as the ﬁnal hits for onward evaluation
from this campaign (Supplementary Table 3). The criteria for
compound selection were based on a selection score (derived
according to Supplementary Table 4) with the resultant hits
illustrated in chemical space in Fig. 3. We employed a simple
ligand-efﬁciency metric, ligand efﬁciency-dependent lipophilicity
index (LELP28), to aid in the prioritisation of the clusters
balancing potency with lipophilicity. Notably, the calculated
LELP for each of the highest scoring hits in each cluster is in the
desirable range (≤10) further conﬁrming the quality of the hit
series identiﬁed.
To further validate the hit molecules from these 9 clusters,
samples were sourced either from the AstraZeneca compound
inventory or through re-synthesis. All 18 samples were
characterised by nuclear magnetic resonance (NMR) and mass
spectroscopy to conﬁrm their chemical structures and by HPLC/
LCMS to establish their purity (Supplementary Table 5 and
Supplementary Data 1). These samples were also subject to
conﬁrmatory re-assessment in both the insect cell screen and Mf
assays for anti-Wolbachia potency alongside conﬁrmation of
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Fig. 2 Overview of the HTS. a Results in ChemGPS chemical space. Purple spheres represent examples of current anti-Wolbachia agents; black points
represent the ~20,000 actives identiﬁed in the primary HTS; orange spheres represent the 360 compounds from the 57 clusters tested in the microﬁlarial
(Mf) assay; green spheres represent the 18 conﬁrmed, potent hits. The position in ChemGPS space indicates a compound’s size, hydrophobicity/
hydrophilicity and ﬂexibility (T1, T2 and T3 deﬁned in ref. 21). The hits span a large proportion of the chemical space covered by the ~6000 compounds. The
3D plot was produced in R using the rgl library (http://cran.r-project.org). b The full screening campaign and triaging process. Each stage includes the total
compounds screened (rectangular box on the right) and hits identiﬁed (circular box on the right). The screen used (C6/36 (wAlbB) or Brugia malayi Mf)
and screening location (AstraZeneca or A·WOL) are indicated on the left. Rational analysis was utilised at every stage based on cheminformatics and
available data
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DMPK properties (LogD7.4, aqueous solubility in pH 7.4 PBS,
human microsomal turnover, rat hepatocyte turnover and human
plasma protein binding) (Fig. 4, Supplementary Figure 1 and
Supplementary Table 4).
Based on these in vitro assessments and further scrutiny by
A·WOL and AstraZeneca, the 9 hit series were placed into three
categories, with each category containing representatives that
have a similar balance between potency and DMPK properties.
(Fig. 4, Category 3 hits are included in Supplementary Figure 1).
From previous hit to lead optimisation studies strong anti-
Wolbachia potency in the in vitro assays was found to be a
reliable indicator of the potential of a chemotype to translate to
acceptable in vivo anti-Wolbachia potency in the adult B. malayi
mouse model29,30. Thus, this parameter was used as a key
component for the following categorisation. Cluster 1, 2 and 3
were placed into Category 1 (Fig. 4), with all representatives
expressing good potency in the Mf assay, superior to doxycycline
in the same assay (EC50= 250 nM). In terms of DMPK proper-
ties, all Category 1 hit series have good physiochemical properties,
i.e. aqueous solubility, but less than optimal metabolic stability.
The balance of key properties for representative hits 1A–3A is
depicted in radar plots (Fig. 4, desirable zone in shaded grey) and
this representation identiﬁes the potential metabolic (rat
hepatocytes or human microsome) liabilities that need to be
addressed moving forward.
Category 2 includes Clusters 4, 5 and 6 (Fig. 4). Representative
pyrrolidinyl thiazole hit 4A (Cluster 4) has strong insect cell
screen activity and good in vitro Mf potency. Solubility is
also excellent for this molecule; however, the human microsomal
stability is poor and this feature should be targeted in
optimisation studies following identiﬁcation of the metabolic
weak-spots through metabolite proﬁling studies. Representative
imidazole carboxamide 5A (Cluster 5) has comparatively good
Mf in vitro potency with lower solubility and moderate
metabolic stability. Medicinal chemistry optimisation should
focus on manipulation of one or both aromatic ring systems
in this hit series to block P450 hydroxylation and should
aim to reduce P450 interactions by lowering the overall
lipophilicity. Radar plot analysis of 5A shows that this starting
point has an excellent balance of all round properties that
map onto the target feature set for hit prioritisation. Whilst
cluster hit 6A has lower potency than representatives 4A or
5A, it does express very good in vitro human microsomal
stability and acceptable solubility (Fig. 4). These features should
enable a focused hit to lead optimisation on potency enhance-
ment through expanding SAR around both the aromatic ring
on the western side of the molecule, as well as functionalisation
of the 5,6,7,8-tetrahydro-4H-thiazolo[5,4-c]azepin-4-one ring
system.
The three remaining clusters 7, 8 and 9 have in vitro
Mf potency in the range 1–5 µM (Supplementary Figure 1
and Supplementary Table 2). Pyrazole 7A has good measured
solubility and high in vitro metabolic stability making potency-
driven optimisation a primary focus in the hit to lead
optimisation of this chemotype. Hit to lead optimisation of
both 8A and 9A will likely be more challenging and will
require multiparameter optimisation of Mf potency, solubility
and microsomal stability.
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To compare the dynamics of the in vitro phenotype of our hits
with existing anti-Wolbachia therapies, we employed a timed
wash-out strategy (Fig. 5) at 10x EC50 to establish the anti-
Wolbachia time-kill kinetics of the selected chemotypes (1A–5A),
using ﬁve replicates per compound. Time-kill kinetics of
tetracyclines (doxycycline 1.21 µM and minocycline 0.9 µM)
and rifampicin (0.2 µM) indicated that it takes >2 days to achieve
a maximal Wolbachia reduction in this assay (70–90% when
normalised to vehicle control). In contrast, all hit chemotypes
(1A–5A) demonstrated this maximal activity (>70% Wolbachia
reduction) after just 2 days exposure (ranging from 1.61 to 2.96
µM). Even more strikingly, after just a single day of exposure,
doxycycline is inactive (9% Wolbachia reduction), yet chemotype
3A showed a 42% reduction and chemotypes 1A, 2A, 4A and 5A
achieved Wolbachia reductions of 57–67%. This data presents a
dramatic temporal shift in the exposure time of <2 days to achieve
a maximal Wolbachia reduction for these chemotypes compared
to >4 days for known proof of concept anti-Wolbachia drugs.
The data indicates that these small drug like chemotypes
mediate Wolbachia depletion much more rapidly than all existing
anti-Wolbachia drugs. Optimisation and further development of
any one of these ﬁve chemotypes has the potential to deliver
molecules that could radically reduce treatment timeframes,
which is one of the major limitations of the current policy drug,
doxycycline (4–6 weeks regimens) for the treatment of oncho-
cerciasis and lymphatic ﬁlariasis. Furthermore, it is accepted that
time-kill kinetics is a ﬁxed characteristic of a speciﬁc mechanism
of drug action31 and this data suggested these fast-acting hit
chemotypes have different modes of action from those known
anti-Wolbachia drugs.
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Discussion
The opportunity to access industry scale screening has delivered
an enhanced portfolio of anti-Wolbachia chemotypes and
identiﬁed 9 distinct chemical entities that represent excellent
starting points for the discovery of novel drugs for the debilitating
ﬁlarial diseases onchocerciasis and lymphatic ﬁlariasis. Our
goals were achieved through a highly collaborative and
multidisciplinary process synergistically building on the domain
expertise complementarity of the academic and pharmaceutical
groups. Working in partnership a workﬂow from assay validation,
primary screen, to cheminformatic-driven chemotype prioritisa-
tion was achieved within 6 months (Fig. 2). The key component
to the success of this work was the development of a robust
model cell-based HTS, which through a 2 month screening
timeframe maintained an average robust Z′ of 0.72
(0.06 standard deviation (SD) and 8.38% coefﬁcient of variation
(CV)) and average signal to background noise of 22.54
(2.77 SD and 12.27% CV) (Supplementary Figure 2). The primary
screening of ~1.3 million compounds in 2 months represents
a >25 fold increase in throughput compared to previous
screens (25,000 to ~650,000 compounds per month)18. To put
this in real terms, running the previous screens18, even
at full capacity, it would take over 4 years to complete the
1.3 million compounds described in this work. To date, our
campaign is the highest throughput screen applied to anthel-
minthic NTD drug discovery ever undertaken, progressing not
only the capacity from thousands to millions of compounds,
but also increasing the number of hits and chemotypes by the
same magnitude.
The 9 hit series identiﬁed in this campaign are not only new
anti-Wolbachia chemotypes, but also novel antibacterial chemo-
types. The only series to appear in the literature is Cluster 1; 4-
piperidino pyrimidines, which are selective inhibitors of 2,3-
oxidosqualene cyclase-lanosterol synthase in the cholesterol
biosynthesis pathway32. Intriguingly Wolbachia are known to
perturb cholesterol homoeostasis in infected host cells33.
In conclusion, we have described the ﬁrst industrial scale
anthelmintic NTD HTS campaign, a primary assessment of a 1.3
million compound library, a secondary concentration response
screen of ~6000 compounds, and cheminformatic prioritisation
and time-kill analysis to deliver a prioritised set of high-quality
starting points for hit to lead optimisation efforts. The proﬁles of
9 prioritised hit chemotypes are described, with measured
potency, physicochemical properties and DMPK analysis together
with an assessment of the key areas of focus for onward medicinal
chemistry optimisation studies. In vitro analysis of killing kinetics
indicates that these fast-acting antibacterial agents have
mechanisms of action different from any established anti-Wol-
bachia drugs which inhibit protein synthesis. Target identiﬁcation
studies of these fast-acting hits should reveal unexplored targets
for not only the treatment of ﬁlarial disease but also generic
antibacterial discovery.
Methods
Cell culture. The mosquito (Aedes albopictus) derived cell line C6/36 (ATCC® CRL
1660), stably infected with Wolbachia pipientis wAlbB (C6/36(wAlbB)), was
maintained in Leibovitz L15 medium containing 2 mM L-glutamine, 1% non-
essential amino acids, 2% tryptose phosphate broth and 20% heat-inactivated foetal
bovine serum (FBS) at 26 °C18. This screen exclusively used cells from the large-
scale cryopreserved batch produced as part of this campaign by culturing the cells
at scale before cryopreservation (90% FBS and 10% DMSO). This produced a cell
bank of 190 × 1ml cryovials containing 3 × 107 cells per vial.
The human monocytic THP-1 cell line (ATCC® TIB-202) used for mammalian
cytotoxicity evaluation was routinely cultured in roller bottles. Growth media
consisted of RPMI 1640 supplemented with 10% FBS and 2mM L-glutamine. Cells
were maintained at 37 °C with 95% humidity in 5% CO2 in a shaking incubator.
They were passaged every 2–3 days to ensure conﬂuency did not exceed 1.5 × 106
cells/ml.
Mammalian cell viability counter-screen. All compounds selected for secondary
IC50 screen were tested in parallel for mammalian cell viability using the CellTiter-
Blue® Cell Viability Assay. THP1 cells were removed from culture and plated at 1 ×
104 cells/well (40 µl) into 384-well assay ready plates and incubated at 37 °C, 5%
CO2 for 48 h at 95% humidity. After the addition of CellTiter-Blue Viability
reagent (8 µl of a 1:6 dilution) the assay plates were incubated for a further 2 h
before ﬂuorescence detected using a PerkinElmer EnVision™ plate reader.
Wolbachia speciﬁc primary antibody production. The antibody was made by
Covance® by immunising ﬁve speciﬁc pathogen-free rabbits with Wolbachia
peptidoglycan-associated lipoprotein from B. malayi (wBmPAL) produced and
donated by New England BioLabs34. The antiserum was obtained and the anti-
wBmPAL antibody puriﬁed by afﬁnity column chromatography. From this we
gained 350 ml of antibody.
Primary HTS and secondary IC50 screen assay set up. On day 0, a single
cryovial was recovered and the cells washed before being transferred to a T225 cm2
ﬂask. After a 7-day recovery Wolbachia infection level (quality control (QC)) was
checked by SYTO®11 DNA staining of both the host cell nuclei and intracellular
Wolbachia. The end-point read out from the Operetta® high content imaging
system (Perkin Elmer) was the percentage of cells infected with Wolbachia. This
was obtained from cytoplasm texture analysis by the associated Harmony® soft-
ware18. Cells with a >50% of the population infected with Wolbachia were classed
as having a good Wolbachia level and therefore used for screening through addi-
tion of 2000 cells per well into assay ready 384-well plates containing the test
compounds. This resulted in a ﬁnal screening concentration of 10 µM. Each plate
included on-board controls; vehicle/DMSO (total/maximum Wolbachia signal) or
doxycycline 5 µM (null/minimum Wolbachia signal), resulting in single shot
screening of 352 compounds per plate for the primary screen. The secondary IC50
screening plates were prepared in a similar way containing 36 compounds in a 10-
point concentration range from 30 µM to 1.5 nM (1 in 3 serial dilution) in a
serpentine pattern. QC plates were also created including full columns of the
following controls; DMSO (total/max), 5 μM doxycycline (null/min), as well as
50 nM doxycycline (reference/medium Wolbachia signal). Daily batches contained
~150 compound plates in addition to the QC plates. Each compound plate was foil
sealed before incubation for 7 days at 26 °C, 95% humidity and atmospheric air.
Anti-Wolbachia and cytotoxicity HTS results characterisation. After 7 days of
drug incubation, the plates were loaded into the fully automated BioCel system
which performed the following additions; ﬁxation and DNA staining (1.8%
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Fig. 5 Anti-Wolbachia time-kill analysis. Representatives from the top ﬁve
clusters (1A–5A), as well as established anti-Wolbachia antibacterials
(doxycycline (white), minocycline (grey), rifampicin (black)) were assessed
after exposure for 1 day and 2 days before washing and further incubation
until the standard 6-day read out. wsp:gst ratio was normalised to the
DMSO vehicle control resulting in a read out of mean percentage reduction
from control. Doxycycline day 6 treatment represents the result for
exposure to doxycycline at 5 µM for a full 6 days (no wash). The box
extends from the 25th to the 75th percentile with the median presented by
the central line. The whiskers are set at the minimum and maximum
therefore indicating the range from ﬁve replicates. The cluster number is
indicated by colour: cluster 1 (dark blue), 2 (magenta), 3 (teal), 4 (dark
gold), and 5 (light blue)
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formaldehyde+ 0.6 µg/ml Hoechst 33342, 20 min), permeabilisation (80 μl of
PBS+ 0.25% Triton-X 100, 30 min), blocking (PBS+ 6% BSA, 40 min), overnight
incubation in the Wolbachia-speciﬁc anti-wBmPAL primary antibody34 (30 µl of
1 in 2000) followed by washing (PBS+ 0.05% polysorbate) and a 1 h incubation
in the secondary antibody (30 µl of 1 in 400), Alexa Fluor® 680 Goat Anti-Rabbit
IgG (A-21076 Life Technologies™, far red ﬂuorescence), before ﬁnal washing
(PBS+ 0.05% polysorbate) and left in 40 μl of PBS with the plates foil sealed.
Between each stage the wells were emptied of liquid.
The ﬁxed antibody-stained plates were read on both a TTP acumen®
(Wolbachia analysis) and a PerkinElmer EnVision™ (Hoechst host cell toxicity
analysis) encompassed in two HighRes Biosolutions automated systems. The
ﬁnal reads out were; total Wolbachia area per well (gated for excessive area and
ﬂuorescence intensity, assumed to be artefacts) (TTP acumen®) and a single
Hoechst ﬂuorescent read out per well indicating the host cell density (PerkinElmer
EnVision™). Per plate, the acumen® read was processed in ~20 min, whilst the
EnVision™ read was obtained in 2 min. Using two acumen®s and the EnVision™,
allowed for the 150 plate batch to be read in 28 h.
HTS data analysis. Genedata Screener software was used for all analysis, in which
data for toxicity (Hoechst read on the EnVision™) and Wolbachia inhibition
(antibody ﬂuorescence read on the acumen®) were normalised on an individual
plate basis. For the primary screen, the toxicity reads were normalised to the
median read from all compounds on each plate as it is assumed the toxicity level
should be limited and toxic compounds are randomly distributed over the plates in
a given screening batch. The anti-Wolbachia reads were normalised to the
maximum signal (‘Max signal’, DMSO controls) and the minimum signal
(‘Min signal’, doxycycline 5 μM) these, respectively, representing 0% and 100%
inhibition of Wolbachia.
The data was processed to identify ‘hits’ (Wolbachia inhibitors) that present
little or no toxicity to the host cell line with the normalised Wolbachia data ﬁltered
at >80% inhibition. These active compounds were further annotated to identify
those with >60% inhibition (i.e. toxicity) to the cell line. All plates were monitored
for Z prime, robust Z score and signal to background.
Primary HTS triaging. Chemists from both A∙WOL and AstraZeneca triaged the
hit compounds from the primary screen, based on prior experience. Excluded
compounds included known antibacterials, those previously worked on by A∙WOL
and to those with unwanted characteristics (e.g. PAINS, frequent hitters, known
toxics, explosive risk and genotoxic or reactive metabolite substructures). The
remaining compounds were prioritised based on a balance of molecular weight,
predicted logD, solubility, intrinsic clearance (models for human microsomes
and rat hepatocytes) and chemotype diversity. The selection was made by
simultaneously (i) minimising the deviation from ideal ranges for each of the ﬁve
physicochemical and DMPK properties considered and (ii) maximising the
coverage of available chemotypes, using a Pareto multiobjective optimisation
algorithm implemented in the PipelinePilot software.
Secondary IC50 screen triaging. Fifty-seven clusters with at least three
compounds each were selected for progression based on an overall manual
assessment of anti-Wolbachia activity, mammalian toxicity, measured compound
purity, cluster size, and chemical structure.
Tertiary screening. The two most potent compounds from the 57 prioritised
clusters from the secondary screen triaging were screened in the microﬁlarial (Mf)
assay at a ﬁnal concentration of 5 µM. The Mf were obtained by peritoneal lavage,
using a catheter, of gerbils (Meriones unguiculatus) harbouring a patent infection of
B. malayi35. Mf were puriﬁed using a PD-10 desalting column (Fisher), centrifuged
(311 RCF for 5 min at room temperature) before the addition of 8000 Mf/well of a
96-well plate (100 µl per well) in complete media consisting of RPMI supplemented
with 10% FBS, 1% penicillin streptomycin and 1% amphotericin B. Compounds
were diluted in complete media and 100 µl was added per well, providing a ﬁnal
concentration of 5 µM, with ﬁve replicates per compound. Each plate contained
doxycycline (5 µM) and DMSO controls. After incubation at 37 °C for 6 days in 5%
CO2, visual assessment of Mf motility was performed and scored from 0 to 4 per
well (where 0= no movement and 4= highly motile). DNA extraction per sample
was performed using the QIAmp DNA Mini Kit before quantitative PCR was
performed to obtain the ratio of Wolbachia Surface Protein gene copy number
(wsp) to Glutathione S-Transferase gene copy number (gst)36. The DNA was
ampliﬁed using the primers as indicated in Supplementary Table 6.
The wsp:gst ratio data allowed for normalisation of the Wolbachia level to the
Mf biomass for each well. The change in wsp:gst for each compound compared to
the DMSO control was calculated before normalisation to the onboard doxycycline
control to allow for inter-assay comparison.
Experimental DMPK screening. The DMPK data used for triaging compounds,
including LogD7.4, aqueous solubility, plasma protein binding, microsome and
hepatocyte clearance measurements, were generated using the standard AstraZe-
neca UK high-throughput platform37,38.
Data availability
The data that support the ﬁndings of this study are available on request from the
corresponding author (S.A.W.) with permission from AstraZeneca. The compound
data beyond that shared within the primary publication are not publicly available
due to intellectual property restrictions.
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